Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.

George BM, Kao KS, Kwon HS, Velasco BJ, Poyser J, Chen A, Le AC, Chhabra A, Burnett CE, Cajuste D, Hoover M, Loh KM, Shizuru JA, Weissman IL.

Cell Stem Cell. 2019 Jun 8. pii: S1934-5909(19)30222-X. doi: 10.1016/j.stem.2019.05.018. [Epub ahead of print]

PMID:
31204177
2.

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.

Pang WW, Czechowicz A, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA.

Blood. 2019 May 9;133(19):2069-2078. doi: 10.1182/blood-2018-06-858159. Epub 2019 Feb 11.

PMID:
30745302
3.

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.

Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ.

Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x.

4.

Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice.

Kwon HS, Logan AC, Chhabra A, Pang WW, Czechowicz A, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA.

Blood. 2019 May 9;133(19):2104-2108. doi: 10.1182/blood-2018-06-853879. Epub 2019 Jan 7. No abstract available.

PMID:
30617195
5.

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R.

Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.

6.

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC.

Science. 2018 Mar 2;359(6379):1037-1042. doi: 10.1126/science.aar3246.

7.

SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells.

Goldstone AB, Burnett CE, Cohen JE, Paulsen MJ, Eskandari A, Edwards BE, Ingason AB, Steele AN, Patel JB, MacArthur JW, Shizuru JA, Woo YJ.

J Cardiovasc Transl Res. 2018 Aug;11(4):274-284. doi: 10.1007/s12265-017-9772-y. Epub 2018 Feb 21.

PMID:
29468554
8.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR.

Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. eCollection 2017 Jul 25.

9.

An innovative biologic system for photon-powered myocardium in the ischemic heart.

Cohen JE, Goldstone AB, Paulsen MJ, Shudo Y, Steele AN, Edwards BB, Patel JB, MacArthur JW Jr, Hopkins MS, Burnett CE, Jaatinen KJ, Thakore AD, Farry JM, Truong VN, Bourdillon AT, Stapleton LM, Eskandari A, Fairman AS, Hiesinger W, Esipova TV, Patrick WL, Ji K, Shizuru JA, Woo YJ.

Sci Adv. 2017 Jun 14;3(6):e1603078. doi: 10.1126/sciadv.1603078. eCollection 2017 Jun.

10.

Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis.

Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan Y, Chen Y, Alvarez M, Strober W, Velardi A, Shizuru JA, Wu JY, Chiba S, Negrin RS.

Nat Commun. 2017 May 9;8:15068. doi: 10.1038/ncomms15068.

11.

Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling.

Ho CCM, Chhabra A, Starkl P, Schnorr PJ, Wilmes S, Moraga I, Kwon HS, Gaudenzio N, Sibilano R, Wehrman TS, Gakovic M, Sockolosky JT, Tiffany MR, Ring AM, Piehler J, Weissman IL, Galli SJ, Shizuru JA, Garcia KC.

Cell. 2017 Mar 9;168(6):1041-1052.e18. doi: 10.1016/j.cell.2017.02.011.

12.

Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA.

J Immunol. 2016 Nov 15;197(10):4151-4162. Epub 2016 Oct 10.

13.

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.

Chhabra A, Ring AM, Weiskopf K, Schnorr PJ, Gordon S, Le AC, Kwon HS, Ring NG, Volkmer J, Ho PY, Tseng S, Weissman IL, Shizuru JA.

Sci Transl Med. 2016 Aug 10;8(351):351ra105. doi: 10.1126/scitranslmed.aae0501.

PMID:
27510901
14.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R.

Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.

15.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.

Percival MM, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R.

Bone Marrow Transplant. 2015 Jul;50(7):1004-1006. doi: 10.1038/bmt.2015.62. Epub 2015 Apr 20. No abstract available.

16.

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.

Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S.

Clin Cancer Res. 2015 Aug 15;21(16):3727-39. doi: 10.1158/1078-0432.CCR-14-2824. Epub 2015 Apr 13.

17.

Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation.

Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S.

Am J Transplant. 2015 Mar;15(3):695-704. doi: 10.1111/ajt.13091.

18.

Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S.

Radiat Res. 2014 Aug;182(2):163-9. doi: 10.1667/RR13471.1. Epub 2014 Jul 3.

19.

A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Dvorak CC, Horn BN, Puck JM, Czechowicz A, Shizuru JA, Ko RM, Cowan MJ.

Pediatr Transplant. 2014 Sep;18(6):602-8. doi: 10.1111/petr.12309. Epub 2014 Jun 30.

20.

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Medeiros BC, Tian L, Robenson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Benjamin JE, Weng WK, Negrin RS, Lowsky R.

Blood Cancer J. 2014 May 30;4:e216. doi: 10.1038/bcj.2014.35. No abstract available.

21.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R.

Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.

22.

Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.

Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA.

Blood. 2014 May 1;123(18):2882-92. doi: 10.1182/blood-2013-10-530212. Epub 2014 Mar 3.

23.

B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes.

Rajasekaran N, Wang N, Hang Y, Macaubas C, Rinderknecht C, Beilhack GF, Shizuru JA, Mellins ED.

Clin Exp Immunol. 2013 Oct;174(1):27-37. doi: 10.1111/cei.12163.

24.

Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice.

Chen X, Wang Y, Li Q, Tsai S, Thomas A, Shizuru JA, Cao TM.

Immunogenetics. 2013 Aug;65(8):597-607. doi: 10.1007/s00251-013-0710-0. Epub 2013 May 24.

25.

Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice.

Wang Y, Chen X, Tsai S, Thomas A, Shizuru JA, Cao TM.

Immunogenetics. 2013 Aug;65(8):585-96. doi: 10.1007/s00251-013-0709-6. Epub 2013 May 12.

26.

Host-derived CD4+ T cells attenuate stem cell-mediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice.

Rajasekaran N, Wang N, Truong P, Rinderknecht C, Macaubas C, Beilhack GF, Shizuru JA, Mellins ED.

Arthritis Rheum. 2013 Mar;65(3):681-92. doi: 10.1002/art.37800.

27.

The road to purified hematopoietic stem cell transplants is paved with antibodies.

Logan AC, Weissman IL, Shizuru JA.

Curr Opin Immunol. 2012 Oct;24(5):640-8. doi: 10.1016/j.coi.2012.08.002. Epub 2012 Aug 29. Review.

28.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB.

Blood. 2012 Jun 21;119(25):6145-54. doi: 10.1182/blood-2011-12-395970. Epub 2012 May 4.

29.

Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity.

Müller AM, Shashidhar S, Küpper NJ, Kohrt HE, Florek M, Negrin RS, Brown JM, Shizuru JA.

Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5820-5. doi: 10.1073/pnas.1120237109. Epub 2012 Mar 22.

30.

Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S.

Am J Transplant. 2012 May;12(5):1133-45. doi: 10.1111/j.1600-6143.2012.03992.x. Epub 2012 Mar 8.

31.

Induced immune tolerance for kidney transplantation.

Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S.

N Engl J Med. 2011 Oct 6;365(14):1359-60. doi: 10.1056/NEJMc1107841. No abstract available.

32.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.

Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB.

Blood. 2011 Oct 13;118(15):4070-8. doi: 10.1182/blood-2011-03-341693. Epub 2011 Aug 9.

33.

Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.

Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA.

Biol Blood Marrow Transplant. 2012 Jan;18(1):125-33. doi: 10.1016/j.bbmt.2011.07.009. Epub 2011 Jul 20.

34.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.

Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87. doi: 10.1016/j.bbmt.2011.05.012. Epub 2011 May 25.

35.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.

Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K.

Bone Marrow Transplant. 2012 Apr;47(4):516-21. doi: 10.1038/bmt.2011.106. Epub 2011 May 23.

36.

Rapid reconstitution of antibody responses following transplantation of purified allogeneic hematopoietic stem cells.

Linderman JA, Shizuru JA.

J Immunol. 2011 Apr 1;186(7):4191-9. doi: 10.4049/jimmunol.1003674. Epub 2011 Feb 28.

37.

Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.

Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14721-6. doi: 10.1073/pnas.1009220107. Epub 2010 Aug 2.

38.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM.

J Clin Oncol. 2010 Jun 10;28(17):2859-67. doi: 10.1200/JCO.2009.27.1460. Epub 2010 May 3.

39.

Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.

Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1145-54. doi: 10.1016/j.bbmt.2010.02.022. Epub 2010 Mar 1.

40.

The biology of allogeneic hematopoietic cell resistance.

Shizuru JA, Bhattacharya D, Cavazzana-Calvo M.

Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S2-7. doi: 10.1016/j.bbmt.2009.11.005. Epub 2009 Nov 12. Review.

41.

Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.

Filatenkov A, Müller AM, Tseng WW, Dejbakhsh-Jones S, Winer D, Luong R, Shizuru JA, Engleman EG, Strober S.

J Immunol. 2009 Dec 1;183(11):7196-203. doi: 10.4049/jimmunol.0900159. Epub 2009 Nov 4.

42.

Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.

Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke GN, Sorror M, Hoppe R, Maloney DG, Negrin RS, Shizuru JA, Sandmaier BM.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1314-22. doi: 10.1016/j.bbmt.2009.06.011. Epub 2009 Aug 3.

43.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure.

Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG.

Bone Marrow Transplant. 2010 Feb;45(2):303-9. doi: 10.1038/bmt.2009.152. Epub 2009 Jul 13.

44.

Identification of a major susceptibility locus for lethal graft-versus-host disease in MHC-matched mice.

Cao TM, Lazzeroni LC, Tsai S, Pang WW, Kao A, Camp NJ, Thomas A, Shizuru JA.

J Immunol. 2009 Jul 1;183(1):462-9. doi: 10.4049/jimmunol.0900454. Epub 2009 Jun 12.

45.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R.

Blood. 2009 Jul 30;114(5):1099-109. doi: 10.1182/blood-2009-03-211441. Epub 2009 May 7.

46.

A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice.

Cao TM, Thomas A, Wang Y, Tsai S, Logronio K, Shizuru JA.

Blood. 2009 Jul 2;114(1):202-10. doi: 10.1182/blood-2009-03-208801. Epub 2009 May 5.

47.

Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow.

Tsao GJ, Allen JA, Logronio KA, Lazzeroni LC, Shizuru JA.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3288-93. doi: 10.1073/pnas.0813335106. Epub 2009 Feb 17.

48.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG.

Blood. 2009 Apr 2;113(14):3383-91. doi: 10.1182/blood-2008-07-170746. Epub 2008 Nov 17.

50.

Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.

Müller AM, Duque J, Shizuru JA, Lübbert M.

Oncogene. 2008 Oct 2;27(44):5759-73. doi: 10.1038/onc.2008.196. Epub 2008 Jul 7. Review.

PMID:
18604246

Supplemental Content

Loading ...
Support Center